These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 12595503

  • 1. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice.
    Bao L, Haas M, Kraus DM, Hack BK, Rakstang JK, Holers VM, Quigg RJ.
    J Am Soc Nephrol; 2003 Mar; 14(3):670-9. PubMed ID: 12595503
    [Abstract] [Full Text] [Related]

  • 2. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice.
    Atkinson C, Qiao F, Song H, Gilkeson GS, Tomlinson S.
    J Immunol; 2008 Jan 15; 180(2):1231-8. PubMed ID: 18178863
    [Abstract] [Full Text] [Related]

  • 3. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice.
    Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, Alexander JJ, Anderson RK, Culhane K, Holers VM, Quigg RJ.
    J Immunol; 2002 Apr 01; 168(7):3601-7. PubMed ID: 11907125
    [Abstract] [Full Text] [Related]

  • 4. Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation.
    Bao L, Zhou J, Holers VM, Quigg RJ.
    J Am Soc Nephrol; 2003 Oct 01; 14(10):2516-25. PubMed ID: 14514729
    [Abstract] [Full Text] [Related]

  • 5. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
    Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson GS, Tomlinson S.
    Arthritis Rheum; 2011 Apr 01; 63(4):1076-85. PubMed ID: 21452327
    [Abstract] [Full Text] [Related]

  • 6. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice.
    Sekine H, Reilly CM, Molano ID, Garnier G, Circolo A, Ruiz P, Holers VM, Boackle SA, Gilkeson GS.
    J Immunol; 2001 May 15; 166(10):6444-51. PubMed ID: 11342671
    [Abstract] [Full Text] [Related]

  • 7. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis.
    Alexander JJ, Bao L, Jacob A, Kraus DM, Holers VM, Quigg RJ.
    Biochim Biophys Acta; 2003 Nov 20; 1639(3):169-76. PubMed ID: 14636948
    [Abstract] [Full Text] [Related]

  • 8. The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice.
    Shi Y, Yao W, Sun L, Li G, Liu H, Ding P, Hu W, Xu H.
    BMC Nephrol; 2019 Nov 21; 20(1):424. PubMed ID: 31752725
    [Abstract] [Full Text] [Related]

  • 9. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B.
    Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, Boackle SA, Colten HR, Gilkeson GS.
    J Immunol; 2000 Jan 15; 164(2):786-94. PubMed ID: 10623824
    [Abstract] [Full Text] [Related]

  • 10. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice.
    Song H, Qiao F, Atkinson C, Holers VM, Tomlinson S.
    J Immunol; 2007 Dec 01; 179(11):7860-7. PubMed ID: 18025232
    [Abstract] [Full Text] [Related]

  • 11. Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease.
    Pérez de Lema G, Lucio-Cazaña FJ, Molina A, Luckow B, Schmid H, de Wit C, Moreno-Manzano V, Banas B, Mampaso F, Schlöndorff D.
    Kidney Int; 2004 Sep 01; 66(3):1018-28. PubMed ID: 15327395
    [Abstract] [Full Text] [Related]

  • 12. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice.
    Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, Gilkeson GS.
    Kidney Int; 2004 Jan 01; 65(1):129-38. PubMed ID: 14675043
    [Abstract] [Full Text] [Related]

  • 13. Absence of functional alternative complement pathway alleviates lupus cerebritis.
    Alexander JJ, Jacob A, Vezina P, Sekine H, Gilkeson GS, Quigg RJ.
    Eur J Immunol; 2007 Jun 01; 37(6):1691-701. PubMed ID: 17523212
    [Abstract] [Full Text] [Related]

  • 14. The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition.
    Sekine H, Ruiz P, Gilkeson GS, Tomlinson S.
    Mol Immunol; 2011 Oct 01; 49(1-2):317-23. PubMed ID: 22000720
    [Abstract] [Full Text] [Related]

  • 15. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J, Rupanagudi KV, Kulkarni OP, Darisipudi MN, Allam R, Anders HJ.
    J Immunol; 2011 Sep 15; 187(6):3413-21. PubMed ID: 21849682
    [Abstract] [Full Text] [Related]

  • 16. Complement-dependent apoptosis and inflammatory gene changes in murine lupus cerebritis.
    Alexander JJ, Jacob A, Bao L, Macdonald RL, Quigg RJ.
    J Immunol; 2005 Dec 15; 175(12):8312-9. PubMed ID: 16339572
    [Abstract] [Full Text] [Related]

  • 17. Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury.
    Quigg RJ, He C, Lim A, Berthiaume D, Alexander JJ, Kraus D, Holers VM.
    J Exp Med; 1998 Oct 05; 188(7):1321-31. PubMed ID: 9763611
    [Abstract] [Full Text] [Related]

  • 18. Expression of a soluble complement inhibitor protects transgenic mice from antibody-induced acute renal failure.
    Schiller B, Cunningham PN, Alexander JJ, Bao L, Holers VM, Quigg RJ.
    J Am Soc Nephrol; 2001 Jan 05; 12(1):71-79. PubMed ID: 11134252
    [Abstract] [Full Text] [Related]

  • 19. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor.
    Quigg RJ, Kozono Y, Berthiaume D, Lim A, Salant DJ, Weinfeld A, Griffin P, Kremmer E, Holers VM.
    J Immunol; 1998 May 01; 160(9):4553-60. PubMed ID: 9574562
    [Abstract] [Full Text] [Related]

  • 20. Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivo.
    Hepburn NJ, Chamberlain-Banoub JL, Williams AS, Morgan BP, Harris CL.
    Mol Immunol; 2008 Jan 01; 45(2):395-405. PubMed ID: 17651804
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.